Journal of Nuclear Medicine: 59 (5)

May 1, 2018; Volume 59,Issue 5

Cover image

FEATURED ARTICLE

¹⁷⁷Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. Richard Baum et al. See page 809.

¹⁸F-FEDAC macrophage imaging in arthritis: a new alternative for visualization of active infl ammation? Seock-Jin Chung et al. See page 839.

In this issue

Issue highlights

¹⁷⁷Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
¹⁸F-FEDAC as a Targeting Agent for Activated Macrophages in DBA/1 Mice with Collagen-Induced Arthritis: Comparison with ¹⁸F-FDG
Molecular Imaging in Cancer Drug Development
Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy

MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
Toward Single-Time-Point Image-Based Dosimetry of ¹⁷⁷Lu-PSMA-617 Therapy
Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
Unspecific ¹⁸F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to